Evofem Biosciences commercializes FDA-approved sexual and reproductive health products for women’s health. Its product portfolio includes PHEXX® (lactic acid, citric acid and potassium bitartrate), a hormone-free contraceptive vaginal gel, and SOLOSEC® (secnidazole) 2g oral granules, an oral antibiotic for bacterial vaginosis and trichomoniasis.
Company news commonly covers product sales, operating results, commercialization partnerships, distribution agreements and international regulatory activity for PHEXX and SOLOSEC. Updates also include manufacturing and supply arrangements, stockholder votes, capital-market actions and education or advocacy initiatives tied to women’s health communication.
Evofem Biosciences, Inc. (NASDAQ: EVFM) praised House leaders for advocating coverage of all FDA-approved contraceptives under the Affordable Care Act (ACA). CEO Saundra Pelletier recognized the importance of the House's letter, which requests senior Biden Administration officials to ensure compliance with ACA requirements. The company's product, Phexxi, is a hormone-free contraceptive gel approved by the FDA in May 2020. Evofem focuses on women's reproductive health solutions, including contraception and protection against STIs.
Evofem Biosciences (NASDAQ: EVFM) announced its CEO, Saundra Pelletier, will present at the LD Micro Main Event in Los Angeles from October 12-14, 2021. The presentation is scheduled for October 12 at 12:30 p.m. PT. The company recently launched a new campaign, "House Rules," on September 9, 2021, to promote its hormone-free contraceptive, Phexxi. The campaign has successfully increased media coverage, site traffic, and telehealth visits, enhancing Phexxi prescription growth. Interested parties can register for the virtual presentation via the company website.
Evofem Biosciences, Inc. (NASDAQ: EVFM) announced the publication of a manuscript in Advances in Therapy, discussing variability in contraceptive clinical trial designs and their impact on efficacy outcomes. The study highlights challenges in comparing efficacy across non-hormonal and hormonal contraception due to variations in trial protocols. Key findings show that the exclusion of certain menstrual cycles can misrepresent the effectiveness of contraceptives. The paper aims to raise awareness among healthcare providers regarding these nuances, thereby improving contraceptive counseling.
Evofem Biosciences (NASDAQ: EVFM) announced the presentation of seven clinical trial data sets on its products, Phexxi and EVO100, at four medical society meetings in October 2021. Leading the presentations is Dr. Brandi Howard, who highlighted significant interest from healthcare providers. The posters will cover topics including genitourinary symptoms and the effectiveness of the vaginal pH modulator in preventing STIs. Notably, the AMPREVENCE study showcased statistically significant reductions in the risk of chlamydia and gonorrhea infections. The abstracts will be published in relevant medical journals.
Summary not available.
Evofem Biosciences (NASDAQ: EVFM) announced that CEO Saundra Pelletier will participate in two investor conferences. The first is the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, featuring a corporate presentation at 7:00 a.m. ET. The second is the Morgan Stanley Virtual Global Healthcare Conference on September 14, 2021, in a fireside chat at 12:30 p.m. ET. Both events will be webcast and available for 30 days on the company’s website. Evofem focuses on women's sexual and reproductive health, including innovative contraceptive solutions.
Evofem Biosciences (NASDAQ: EVFM) reported a net loss of $33.4 million, improving from $46.2 million in Q1 2021. Phexxi sales surged by 68% to $1.9 million, with a 47% increase in prescriptions and a 52% growth in prescriber base. Operating expenses fell by 6% to $43 million, despite a 17% rise in R&D costs to $8.5 million. A celebrity campaign is set to launch in September 2021 to boost brand awareness. Cash and equivalents stood at $47 million as of June 30, 2021. The company remains on track for the EVOGUARD trial completion by year-end.
Evofem Biosciences, Inc. (NASDAQ: EVFM) will host a webcast and conference call on August 11, 2021, at 4:30 p.m. ET to discuss its financial results for the second quarter ended June 30, 2021. Participants can access the event live and via archived presentation at this link. For phone participation, dial (866) 503-5561 (U.S.) or (253) 336-2965, using conference ID 9190716. An audio replay will be available for 24 hours post-call. Evofem focuses on innovative women's health solutions, including its FDA-approved product Phexxi®.
Evofem Biosciences (NASDAQ: EVFM) reported strong growth for its hormone-free contraceptive Phexxi in Q2 2021, dispensing over 14,000 units and involving more than 5,400 healthcare providers. Notably, 60% of new users are aged 18 to 34, with many switching from hormonal methods. CEO Saundra Pelletier highlighted a growing trend among women prioritizing hormone-free options. Detailed metrics will be discussed in the upcoming earnings call in August, further solidifying Phexxi's position in women's reproductive health.
Evofem Biosciences (NASDAQ: EVFM) announced that CEO Saundra Pelletier will present at the Jefferies Virtual Healthcare Conference on June 4, 2021, at 10:30 a.m. ET. The presentation will be available via live webcast and archived for 30 days. The company focuses on developing products for women's sexual and reproductive health, including the hormone-free contraceptive Phexxi, launched in September 2020. Evofem is also evaluating the EVO100 candidate for preventing specific STIs in an ongoing Phase 3 clinical trial, EVOGUARD.